Literature DB >> 21137597

Pseudoislets as primary islet replacements for research: report on a symposium at King's College London, London UK.

Shanta J Persaud1, Catherine Arden, Peter Bergsten, Adrian J Bone, James Brown, Simon Dunmore, Moira Harrison, Astrid Hauge-Evans, Catriona Kelly, Aileen King, Tania Maffucci, Claire E Marriott, Neville McClenaghan, Noel G Morgan, Christina Reers, Mark A Russell, Mark D Turner, Emma Willoughby, Mustafa Y G Younis, Z L Zhi, Peter M Jones.   

Abstract

Laboratory-based research aimed at understanding processes regulating insulin secretion and mechanisms underlying β-cell dysfunction and loss in diabetes often makes use of rodents, as these processes are in many respects similar between rats/mice and humans. Indeed, a rough calculation suggests that islets have been isolated from as many as 150,000 rodents to generate the data contained within papers published in 2009 and the first four months of 2010. Rodent use for islet isolation has been mitigated, to a certain extent, by the availability of a variety of insulin-secreting cell lines that are used by researchers world-wide. However, when maintained as monolayers the cell lines do not replicate the robust, sustained secretory responses of primary islets which limits their usefulness as islet surrogates. On the other hand, there have been several reports that configuration of MIN6 β-cells, derived from a mouse insulinoma, as three-dimensional cell clusters termed ‘pseudoislets’ largely recapitulates the function of primary islet β-cells. The Diabetes Research Group at King’s College London has been using the MIN6 pseudoislet model for over a decade and they hosted a symposium on “Pseudoislets as primary islet replacements for research”, which was funded by the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), in London on 15th and 16th April 2010. This small, focused meeting was conceived as an opportunity to consolidate information on experiences of working with pseudoislets between different UK labs, and to introduce the theory and practice of pseudoislet culture to laboratories working with islets and/or β-cell lines but who do not currently use pseudoislets. This short review summarizes the background to the development of the cell line-derived pseudoislet model, the key messages arising from the symposium and emerging themes for future pseudoislet research.

Entities:  

Mesh:

Year:  2010        PMID: 21137597     DOI: 10.4161/isl.2.4.12557

Source DB:  PubMed          Journal:  Islets        ISSN: 1938-2014            Impact factor:   2.694


  5 in total

1.  Aggregation of Engineered Human β-Cells Into Pseudoislets: Insulin Secretion and Gene Expression Profile in Normoxic and Hypoxic Milieu.

Authors:  Marie-José Lecomte; Séverine Pechberty; Cécile Machado; Sandra Da Barroca; Philippe Ravassard; Raphaël Scharfmann; Paul Czernichow; Bertrand Duvillié
Journal:  Cell Med       Date:  2016-08-12

2.  In vitro formation of β cell pseudoislets using islet-derived endothelial cells.

Authors:  Michael G Spelios; Lauren A Kenna; Bonnie Wall; Eitan M Akirav
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

3.  Calcium current inactivation rather than pool depletion explains reduced exocytotic rate with prolonged stimulation in insulin-secreting INS-1 832/13 cells.

Authors:  Morten Gram Pedersen; Vishal Ashok Salunkhe; Emma Svedin; Anna Edlund; Lena Eliasson
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

4.  The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease.

Authors:  Melanie L Graham; Mark J Prescott
Journal:  Eur J Pharmacol       Date:  2015-03-28       Impact factor: 4.432

5.  Bioengineered human pseudoislets form efficiently from donated tissue, compare favourably with native islets in vitro and restore normoglycaemia in mice.

Authors:  Yang Yu; Anissa Gamble; Rena Pawlick; Andrew R Pepper; Bassem Salama; Derek Toms; Golsa Razian; Cara Ellis; Antonio Bruni; Boris Gala-Lopez; Jia Lulu Lu; Heather Vovko; Cecilia Chiu; Shaaban Abdo; Tatsuya Kin; Greg Korbutt; A M James Shapiro; Mark Ungrin
Journal:  Diabetologia       Date:  2018-07-03       Impact factor: 10.122

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.